MODERATOR(S)
Emily Weg, MD - Weill Cornell Medicine
session DESCRIPTION
Microboosting in prostate cancer can improve PSA control outcomes and is isotoxic based on level 1 evidence. Despite this, its adoption in practice is slow. There are many reasons for this including comfort in appropriately contouring the dominant intraprostatic lesion, defining appropriate CTV/PTV margins, and planning constraints. The work flow with different techniques (CT based, MRI based, brachy based) for microboosting are also different and each has specific pros/cons. The purpose of this session is to review the various ways of doing a microboost to help the audience feel more comfortable with microboosting and determining the way that will work best in their practice to start doing this.
learning objectives
- Discuss contouring tools to support microboosting in prostate cancer.
- Discuss the workflow for microboosting with CT and MRI based platforms.
- Discuss the workflow for microboosting with a brachytherapy based platform.
Credits
| AMA PRA Category 1 Credits: | 1.00 |
Presentations
-
05:00pm - 05:02pm ETSpeaker: Emily Weg, MD - Weill Cornell Medicine, New York
-
05:02pm - 05:17pm ETSpeaker: Neil Desai, MD - University of Texas Southwestern Medical Center, Dallas
-
05:17pm - 05:32pm ETSpeaker: Tyler Seibert, MD, PhD - University of California San Diego, La Jolla
-
05:32pm - 05:47pm ETSpeaker: Mitchell Kamrava, MD, MS - Cedars Sinai Medical Center , LA
-
05:47pm - 06:00pm ETSpeaker: Emily Weg, MD - Weill Cornell Medicine, New York